Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02780089 · ClinicalTrials.gov registry record
Study in Patients With Unresectable And Metastatic Melanoma: The Optimize Study
A clinical trial, sponsored by Bristol-Myers Squibb.
- Completed
- Registry status
- 408
- Enrollment target
NCT02780089: Completed study, sponsored by Bristol-Myers Squibb.
NCT02780089 is a clinical trial that has completed, run by Bristol-Myers Squibb. The registered enrollment target is 408 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02780089 has completed, sponsored by Bristol-Myers Squibb.
- COMPLETED
- Registry status
- 408 participants
- Enrollment target
Study Summary
This study evaluates the different patterns of care for patients who have unresectable or metastatic melanoma. The dosing, duration, regimen, indication, and treatments will be observed. The survival rate of these patients will also be observed.
Primary Outcome
To assess the selection and sequencing of drugs and practice patterns used to treat unresectable and metastatic melanoma (e.g. immune checkpoint agents, targeted agents, or combination therapies) in a real-world setting. Reasons for initial treatment decisions across and between drug classes, changes in treatment, and discontinuation will be recorded (e.g. lack of benefit, safety, cost, or other barriers to care).
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 408 participants |
| Start Date | 2015-10-23 |
| Est. Completion | 2020-09-08 |
What the finished NCT02780089 record still lists
NCT02780089 is an observational study that tracks outcomes without assigning an intervention. The registered 408 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 0 interventions.
NCT02780089 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02780089 about?
NCT02780089 is a clinical study titled "Study in Patients With Unresectable And Metastatic Melanoma: The Optimize Study". This study evaluates the different patterns of care for patients who have unresectable or metastatic melanoma. The dosing, duration, regimen, indication, and treatments will be observed. The survival rate of these patients will also be observed.
What is the current status of trial NCT02780089?
This trial is currently completed. The enrollment target is 408 participants. The study started on 2015-10-23. Estimated completion is 2020-09-08.
Who is sponsoring clinical trial NCT02780089?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04835428 · 408 participants · NA
STAND - Study of the AGN1 LOEP SV Kit Compared to PMMA in Patients With Vertebral Compression Fractures
- NCT05836324 · 408 participants · Phase 1
A Study to Evaluate the Safety of INCA33890 in Participants With Advanced or Metastatic Solid Tumors
- NCT05863195 · 408 participants · Phase 3
Testing Pump Chemotherapy in Addition to Standard of Care Chemotherapy Versus Standard of Care Chemotherapy Alone for Patients With Unresectable Colorectal Liver Metastases: The PUMP Trial
- NCT06612268 · 408 participants · Phase 3
A Study to Evaluate How Well Etavopivat Works in People With Sickle Cell Disease
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI